Published online before print February 15, 2006, doi:10.1212/01.wnl.0000201252.57661.e1)
NEUROLOGY 2006;66:664-671
© 2006 American Academy of Neurology
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease
The NINDS NET-PD Investigators*
Address correspondence and reprint requests to Dr. Bernard Ravina, 1351 Mt. Hope Ave., Suite 220, Rochester, NY 14610; e-mail: Bernard.ravina{at}ctcc.rochester.edu
Background: Creatine and minocycline were prioritized for testing in Phase II clinical trials based on a systematic evaluation of potentially disease modifying compounds for Parkinson disease (PD).
Objective: To test whether creatine and minocycline alter the course of early PD relative to a predetermined futility threshold for progression of PD in a randomized, double-blind, Phase II futility clinical trial. Agents that do not perform better than the futility threshold are rejected as futile and are not considered for further study.
Methods: Participants had a diagnosis of PD within 5 years, but did not require medications for the management of symptoms. The primary outcome was the change in the total Unified Parkinson’s Disease Rating Scale (UPDRS) score from baseline to either the time when there was sufficient disability to warrant symptomatic therapy for PD or 12 months, whichever came first. Subjects were randomized 1:1:1 to receive creatine 10 g/day, minocycline 200 mg/day, or matching placebo. The futility threshold was set as a 30% reduction in UPDRS progression based on the placebo/tocopherol arm of the Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism (DATATOP) trial. p Values  0.1 indicate futility.
Results: Two hundred subjects were randomized to the three groups. Neither creatine (p = 0.96) nor minocycline (p = 0.66) could be rejected as futile based on the DATATOP futility threshold. The rate of progression for the calibration placebo group fell outside the 95% CI for the DATATOP historical control. In a sensitivity analysis, based on the threshold derived from the calibration placebo group, again neither drug could be rejected as futile. Tolerability was 91% in the creatine group and 77% in the minocycline group. Common adverse events included upper respiratory symptoms (26%), joint pain (19%), and nausea (17%).
Conclusions: Both creatine and minocycline should be considered for definitive Phase III trials to determine if they alter the long term progression of Parkinson disease (PD). Additional factors must be weighed before selecting agents for Phase III trials, including safety, tolerability, activity, cost, and availability of these two agents in comparison with other agents currently in development for PD.
Editorial, see page 626
See also pages 628 and 660
*The NINDS NET-PD Investigators are listed in the Appendix.
Sponsored by the NIH (National Institute of Neurological Disorders and Stroke), U01NS043127, U01NS043128, and U10NS44415 through 44555.
Disclosure: The authors report no conflicts of interest.
Received April 4, 2005. Accepted in final form November 30, 2005.
This article has been cited by other articles:
|
|
|
|
 
M. Boggild, J. Palace, P. Barton, Y. Ben-Shlomo, T. Bregenzer, C. Dobson, and R. Gray
Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator
BMJ,
December 2, 2009;
339(dec02_1):
b4677 - b4677.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Parashos, C. J. Swearingen, K. M. Biglan, I. Bodis-Wollner, G. S. Liang, G. W. Ross, B. C. Tilley, L. M. Shulman, and for the NET-PD Investigators
Determinants of the Timing of Symptomatic Treatment in Early Parkinson Disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience
Arch Neurol,
September 1, 2009;
66(9):
1099 - 1104.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. W. Olanow, M. B. Stern, and K. Sethi
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Neurology,
May 26, 2009;
72(21_Supplement_4):
S1 - S136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Murata, A. Rosell, R. H. Scannevin, K. J. Rhodes, X. Wang, and E. H. Lo
Extension of the Thrombolytic Time Window With Minocycline in Experimental Stroke
Stroke,
December 1, 2008;
39(12):
3372 - 3377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Wang, S. Zhu, Z. Pei, M. Drozda, I. G. Stavrovskaya, S. J. Del Signore, K. Cormier, E. M. Shimony, H. Wang, R. J. Ferrante, et al.
Inhibitors of Cytochrome c Release with Therapeutic Potential for Huntington's Disease
J. Neurosci.,
September 17, 2008;
28(38):
9473 - 9485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-M. Gao, P. T. Kotzbauer, K. Uryu, S. Leight, J. Q. Trojanowski, and V. M.-Y. Lee
Neuroinflammation and Oxidation/Nitration of {alpha}-Synuclein Linked to Dopaminergic Neurodegeneration
J. Neurosci.,
July 23, 2008;
28(30):
7687 - 7698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. P. Godoy, R. Tarelli, C. C. Ferrari, M. I. Sarchi, and F. J. Pitossi
Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease
Brain,
July 1, 2008;
131(7):
1880 - 1894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Marras and A. Lang
Invited Article: Changing concepts in Parkinson disease: Moving beyond the Decade of the Brain
Neurology,
May 20, 2008;
70(21):
1996 - 2003.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bogdanov, W. R. Matson, L. Wang, T. Matson, R. Saunders-Pullman, S. S. Bressman, and M. F. Beal
Metabolomic profiling to develop blood biomarkers for Parkinson's disease
Brain,
February 1, 2008;
131(2):
389 - 396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Zhang, V. Anantharam, A. Kanthasamy, and A. G. Kanthasamy
Neuroprotective Effect of Protein Kinase C{delta} Inhibitor Rottlerin in Cell Culture and Animal Models of Parkinson's Disease
J. Pharmacol. Exp. Ther.,
September 1, 2007;
322(3):
913 - 922.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Ravina, R. Camicioli, P. G. Como, L. Marsh, J. Jankovic, D. Weintraub, and J. Elm
The impact of depressive symptoms in early Parkinson disease
Neurology,
July 24, 2007;
69(4):
342 - 347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Mitsumoto
Mitochondrial Nutrition as a Strategy for Neuroprotection in Parkinson's Disease--Research Focus in the Department of Alternative Medicine and Experimental Therapeutics at Hokuriku University
Evid. Based Complement. Altern. Med.,
June 1, 2007;
4(2):
263 - 265.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Hass, M. A. Collins, and J. L. Juncos
Resistance Training With Creatine Monohydrate Improves Upper-Body Strength in Patients With Parkinson Disease: A Randomized Trial
Neurorehabil Neural Repair,
March 1, 2007;
21(2):
107 - 115.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. C. Tilley and W. R. Galpern
Screening Potential Therapies: Lessons Learned From New Paradigms Used in Parkinson Disease
Stroke,
February 1, 2007;
38(2):
800 - 803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The NINDS NET-PD Investigators
A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease
Neurology,
January 2, 2007;
68(1):
20 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. K. Cheung, P. H. Gordon, and B. Levin
Selecting promising ALS therapies in clinical trials
Neurology,
November 28, 2006;
67(10):
1748 - 1751.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bender, W. Koch, M. Elstner, Y. Schombacher, J. Bender, M. Moeschl, F. Gekeler, B. Muller-Myhsok, T. Gasser, K. Tatsch, et al.
Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial.
Neurology,
October 10, 2006;
67(7):
1262 - 1264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Schwid and G. R. Cutter
Futility studies: Spending a little to save a lot
Neurology,
March 14, 2006;
66(5):
626 - 627.
[Full Text]
[PDF]
|
|
|
|
